全文获取类型
收费全文 | 9219篇 |
免费 | 420篇 |
国内免费 | 48篇 |
专业分类
耳鼻咽喉 | 44篇 |
儿科学 | 241篇 |
妇产科学 | 82篇 |
基础医学 | 1484篇 |
口腔科学 | 349篇 |
临床医学 | 827篇 |
内科学 | 1633篇 |
皮肤病学 | 112篇 |
神经病学 | 777篇 |
特种医学 | 803篇 |
外科学 | 1236篇 |
综合类 | 29篇 |
一般理论 | 1篇 |
预防医学 | 439篇 |
眼科学 | 69篇 |
药学 | 751篇 |
中国医学 | 23篇 |
肿瘤学 | 787篇 |
出版年
2023年 | 29篇 |
2022年 | 57篇 |
2021年 | 79篇 |
2020年 | 58篇 |
2019年 | 112篇 |
2018年 | 129篇 |
2017年 | 107篇 |
2016年 | 133篇 |
2015年 | 197篇 |
2014年 | 261篇 |
2013年 | 396篇 |
2012年 | 552篇 |
2011年 | 602篇 |
2010年 | 353篇 |
2009年 | 359篇 |
2008年 | 512篇 |
2007年 | 597篇 |
2006年 | 566篇 |
2005年 | 576篇 |
2004年 | 550篇 |
2003年 | 546篇 |
2002年 | 604篇 |
2001年 | 134篇 |
2000年 | 101篇 |
1999年 | 146篇 |
1998年 | 142篇 |
1997年 | 143篇 |
1996年 | 122篇 |
1995年 | 94篇 |
1994年 | 91篇 |
1993年 | 85篇 |
1992年 | 65篇 |
1991年 | 69篇 |
1990年 | 64篇 |
1989年 | 50篇 |
1988年 | 49篇 |
1987年 | 42篇 |
1986年 | 52篇 |
1985年 | 64篇 |
1984年 | 59篇 |
1983年 | 48篇 |
1982年 | 52篇 |
1981年 | 58篇 |
1980年 | 49篇 |
1979年 | 30篇 |
1978年 | 39篇 |
1977年 | 32篇 |
1976年 | 35篇 |
1975年 | 38篇 |
1974年 | 28篇 |
排序方式: 共有9687条查询结果,搜索用时 15 毫秒
101.
First experience with gamma probe guided sentinel lymph node surgery in penile cancer 总被引:3,自引:0,他引:3
Wawroschek F Vogt H Bachter D Weckermann D Hamm M Harzmann R 《Urological research》2000,28(4):246-249
Because of the curative approach, the detection of lymph node metastases in squamous cell carcinoma (SCC) of the penis is
of significant clinical relevance. Sentinel lymph node (SLN) identification by means of lymphangiography has been proven to
be insufficiently safe. However, the high morbidity of inguinal lymphadenectomy and the considerable individual variability
regarding the location of lymph node metastases justify the necessity of a technique that enables the identification of SLNs.
Since 1998, SLNs have been intraoperatively identified and selectively dissected, after peritumoral injection of technetium-99m
nanocolloid and using lymphoscintigraphy, in three patients (one with malignant melanoma and two with SCC). At least one SLN
could be detected in each patient. The maximum surgical time was 30 min. There were no severe complications. Lymph node metastases
did not occur in any patient. Upon a mean follow-up of 10 months, all patients are currently free of tumor. Owing to the long-term
results of sentinel lymphadenectomy in malignant melanoma of other locations and our preliminary results with respect to penile
carcinoma, we consider the current method appropriate as the only primary operation for lymph node staging in early stages
and, in combination with modified inguinal lymphadenectomy, in locally advanced stages.
Received: 24 November 1999 / Accepted: 21 April 2000 相似文献
102.
Eva Melzer J?rg Kreuter Rolf Daniels 《European journal of pharmaceutics and biopharmaceutics》2003,56(1):23-27
Cellulose ethers, in particular hypromellose, represent an interesting alternative when emulsions have to be stabilized avoiding conventional low molecular weight surfactants. So far this option has been only described for the formulation of oil-in-water (o/w) emulsions. Since surfactant-free water-in-oil (w/o) emulsions seem to be also attractive as drug carriers, ethyl cellulose, an oil-soluble cellulose derivative, was studied for its ability to stabilize w/o emulsions. Measurements of the interfacial tension confirmed that ethylcellulose was positively adsorbed at the water/oil interface with diverse lipids. Appearance of model emulsions was dependent on the processing temperature. At low temperatures (15 degrees C) cream-like o/w emulsions were obtained. Processing at 30 degrees C yielded fluid w/o-lotions. Investigation of the microstructure showed that the surface of the emulsion droplets was covered with particles which formed a mechanical barrier. These colloidal particles were shown to be a precipitate of ethylcellulose which forms when the polymer which was dissolved in the lipid phase comes into contact with water. Thus, ethylcellulose was demonstrated to represent a new type of particulate polymeric emulsifier. 相似文献
103.
Peter Ericsson Per Norln Maria Bernsand Per Alm Peter Hglund Rolf Hkanson 《Basic & clinical pharmacology & toxicology》2003,93(2):57-65
Abstract: The ECL cells are endocrine/paracrine cells in the acid‐producing part of the stomach. They secrete histamine in response to circulating gastrin. Gastric submucosal microdialysis has been used to study ECL‐cell histamine mobilization in awake rats. In the present study we assess the usefulness and limitations of the technique. Microdialysis probes were implanted in the gastric submucosa. Histological analysis of the stomach wall around the probe revealed a moderate, local inflammatory reaction 1–2 days after implantation; the inflammation persisted for at least 10 days. Experiments were conducted 3 days after the implantation. The “true” submucosal histamine concentration was determined by perfusing at different rates (the zero flow method) or with different concentrations of histamine at a constant rate (the no‐net‐flux method): in fasted rats it was calculated to be 87±5 (means±S.E.M.) nmol/l and 76±9 nmol/l, respectively. The corresponding histamine concentrations in fed rats were 93±5 and 102±8 nmol/l, respectively. With a perfusion rate of 74 μl/hr the recovery of submucosal histamine was 49%, at 34 μl/hr the recovery increased to 83%. At a perfusion rate below 20 μl/hr the microdialysate histamine concentration was close to the actual concentration in the submucosa. The ECL‐cell histamine mobilization was independent of the concentrations of Ca2+ in the perfusion medium (0–3.4 mmol/l Ca2+). In one experiment, histamine mobilization in response to gastrin (10 nmol/kg/hr subcutaneously) was monitored in rats pretreated with prednisolone (60 mg/kg) or indomethacin (15 mg/kg). The two antiinflammatory agents failed to affect the concentration of histamine in the microdialysate either before or during the gastrin challenge, which was in accord with the observation that the inflammatory reaction was modest and that inflammatory cells were relatively few around the probe and in the wall of the probe. In another experiment, rats were given aminoguanidine (10 mg/kg) or metoprine (10 mg/kg) 4 hr before the start of gastrin infusion (5 nmol/kg/hr intravenously). Metoprine (inhibitor of histamine N‐methyl transferase) did not affect the microdialysate histamine concentration, while aminoguanidine (inhibitor of diamine oxidase) raised both basal and gastrin‐stimulated histamine concentrations. We conclude that microdialysis can be used to monitor changes in the concentration of histamine in the submucosa of the stomach, and that the inflammatory reaction to the probe is moderate and does not affect the submucosal histamine mobilization. 相似文献
104.
Elin Lindhagen Pernille‐Julia Vig Hjarnaa Lena E. Friberg Scilla Latini Rolf Larsson 《Drug development research》2004,61(4):218-226
When a candidate drug enters clinical trials, decisions regarding dosing are mainly based on animal data. Occasionally, toxicity problems are faced in the clinic because of unexpected species differences in pharmacokinetics or pharmacodynamics between humans and preclinical species. Fludarabine and topotecan are examples of such drugs. In the first clinical trials of the new agent CHS 828, the maximum tolerated dose was reached earlier than expected from animal data. This paper discusses the issue of species differences in the development of anticancer drugs, and preclinical models for detection and quantification of such differences. Pharmacokinetic and hematological toxicity data of CHS 828 from studies in rats and humans are presented. In vitro sensitivity to CHS 828 and some established cytotoxic agents was measured in lymphocytes from humans and rats and in a panel of human and rodent cell‐lines. 10–100 times higher CHS 828 exposure was tolerated by rats than by patients. In both in vitro cell systems, CHS 828 showed higher potency in human cells compared to rodent cells. A species difference was evident also for fludarabine, but not for doxorubicin and cisplatin. CHS 828 pharmacokinetics were similar across species. In conclusion, the lower tolerance of CHS 828 in humans than in rats could be detected in vitro in cultures of peripheral lymphocytes. Preclinical studies of species differences could help the interpretation of in vivo effect studies as well as the choice of starting dose for clinical trials. We suggest peripheral lymphocytes from different species as a potential model system for such studies. Drug Dev. Res. 61:218–226, 2004. © 2004 Wiley‐Liss, Inc. 相似文献
105.
Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). 总被引:7,自引:0,他引:7
Silke Reinartz Siegmund K?hler Harald Schlebusch Karl Krista Patrick Giffels Kirsten Renke Jens Huober Volker M?bus Rolf Kreienberg Andreas DuBois Paul Sabbatini Uwe Wagner 《Clinical cancer research》2004,10(5):1580-1587
PURPOSE: A Phase I/IIb multicenter study was conducted to evaluate the safety and immunogenicity of the anti-idiotypic antibody vaccine ACA125 that functionally imitates the tumor antigen CA125 in 119 patients with advanced ovarian carcinoma. A preliminary report on the initial 42 patients demonstrated safety and immunogenicity. EXPERIMENTAL DESIGN: Using the complete intention-to-treat population (n = 119) who received a mean of 9.7 ACA125 applications, survival was analyzed with respect to immunological responses. RESULTS: In 81 patients (68.1%), a specific anti-anti-idiotypic antibody (Ab3) response could be induced. Additionally, the development of CA125-specific antibodies (Ab1') and antibody-dependent cell-mediated cytotoxicity of CA125-positive tumor cells was observed in 50.4% and 26.9% of patients, respectively. The median survival of all patients was 19.4 months (range, 0.5-56.1 months). Ab3-positive patients showed a significantly longer survival (median, 23.4 months; P < 0.0001) as compared with Ab3-negative patients (median, 4.9 months). A positive Ab3 response remained associated with longer survival when controlling for other prognostic factors including FIGO (International Federation of Gynecologists and Obstetricians) stage, response to and type of first-line chemotherapy, number of previous treatments, or concomitant antitumor therapy. With regard to safety, repeated vaccination was well tolerated. No serious adverse events related to the application of ACA125 occurred. CONCLUSIONS: Although the uncontrolled design of this study prevents definitive conclusions with respect to subgroups, the data support a relationship between Ab3 response and survival time. Thus, the need for further randomized, controlled clinical trials to establish efficacy of the vaccine ACA125 seems to be indicated. 相似文献
106.
107.
Xi-Hui Yang Randal A Hand Chad A Livasy William G Cance Rolf J Craven 《Tumour biology》2003,24(2):61-69
OBJECTIVE: Tyrosine kinase with immunoglobulin and epidermal growth factor homology domains (Tie-1) is a receptor tyrosine kinase that regulates angiogenesis and antiapoptotic survival signaling. Tie-1 expression is generally associated with endothelial cells and neovascularization. We previously identified Tie-1 in human breast tumor samples using a PCR-based screen for protein kinases expressed in breast tumors. The purpose of this study was to determine the cell types expressing Tie-1, whether Tie-1 is expressed in tumor cells, and to examine the regulation of Tie-1 in breast cancer. METHODS: Tie-1 expression was analyzed by Western blot and immunohistochemistry using an antibody to the carboxy terminus of Tie-1. Tie-1 expression was determined in a variety of cancer cell lines, clinical breast and colon tumor samples, and in corresponding benign tissue from the same patient. Tie-1 expression and distribution in breast tumors was scored by immunohistochemistry. RESULTS: Tie-1 was overexpressed in 14/23 breast tumors compared with 0/9 corresponding normal tissues from the same patients. Immunohistochemistry revealed that Tie-1 was overexpressed in epithelial breast cancer cells and ductal carcinoma in situ. In all breast tumor samples, Tie-1 was expressed as a truncated 40- to 43-kD doublet consisting of the intracellular portion of the protein, which contains the tyrosine kinase catalytic domain. The 40- to 43-kD Tie-1 doublet was expressed in a broad variety of cell lines. CONCLUSIONS: We have shown that breast cancer cells overexpress a cleaved form of the Tie-1 protein. Our results implicate the intracellular domain of Tie-1, which includes the catalytic kinase domain, in breast cancer progression. 相似文献
108.
Claus R?del Gerhard G Grabenbauer Thomas Papadopoulos Werner Hohenberger Hans-Joachim Schmoll Rolf Sauer 《Journal of clinical oncology》2003,21(16):3098-3104
PURPOSE: The purpose of this study was to establish the feasibility and efficacy of preoperative radiotherapy (RT) with concurrent capecitabine and oxaliplatin (XELOX-RT) in patients with rectal cancer. PATIENTS AND METHODS: Thirty-two patients with locally advanced (T3/T4) or low-lying rectal cancer received preoperative RT (total dose, 50.4 Gy). Capecitabine was administered concurrently at 825 mg/m2 bid on days 1 to 14 and 22 to 35, with oxaliplatin starting at 50 mg/m2 on days 1, 8, 22, and 29 with planned escalation steps of 10 mg/m2. End points of the phase II study included downstaging, histopathologic tumor regression, resectability of T4 disease, and sphincter preservation in patients with low-lying tumors. RESULTS: Dose-limiting grade 3 gastrointestinal toxicity was observed in two of six patients treated with 60 mg/m2 of oxaliplatin. Thus, 50 mg/m2 was the recommended dose for the phase II study. Toxicities observed at this dose level were generally mild, with only two cases of short-lived grade 3 diarrhea. Myelosuppression, mainly leukopenia, was restricted to grade 2 in 19% of patients. T-category downstaging was achieved in 17 (55%) of 31 operated patients, and 68% of patients had negative lymph nodes. Pathologic complete response was found in 19% of the resected specimens. Radical surgery with free margins could be performed in 79% of patients with T4 disease, and 36% of patients with tumors < or = 2 cm from the dentate line had sphincter-saving surgery. CONCLUSION: Preoperative XELOX-RT is a feasible and well tolerated treatment. This regimen is proposed for phase III evaluation comparing standard fluorouracil-based therapy with XELOX chemoradiotherapy. 相似文献
109.
Patient-controlled intranasal analgesia: effective alternative to intravenous PCA for postoperative pain relief 总被引:2,自引:0,他引:2
Susanne Toussaint MD DEAA Julia Maidl MD Rolf Schwagmeier MD Hans Walter Striebel MD PhD DEAA 《Journal canadien d'anesthésie》2000,47(4):299-302
PURPOSE: To investigate whether the nasal route for fentanyl administration in patient-controlled analgesia (PCA) provides as effective postoperative analgesia as intravenous PCA. METHODS: Patient-controlled intranasal or intravenous analgesia with fentanyl was investigated in 48 patients (ASA I-III) on the day of surgery (orthopedic, abdominal or thyroid) in a prospective, randomized, double-blind, double-dummy study. Fentanyl was given in a bolus of 25 microg for intranasal and 17.5 microg for i.v. PCA, lockout interval six minutes. The first requested dose was doubled in both groups. Pain intensity (101-point numerical rating scale) and vital parameters were observed at 11 measurement points during the 240 min study. Patients were asked for side effects at every measurement point and for their satisfaction at the end of the study by the same investigator (J.M.). RESULTS: Onset of analgesia, the first reduction in pain intensity on the numerical rating scale, was 21 +/- 11 min (range 15-45 min) in intranasal and 22 +/- 16 min (range 15-90 min) in i.v. PCA. Pain intensity was reduced from 55 +/- 11 to 11 +/- 10 in the intranasal group and from 53 +/- 8 to 11 +/- 6 in the i.v. PCA group. Vital parameters remained stable and side effects were comparable in both groups. The judgement "excellent" or "good" was given by 21 of 23 patients treated intranasally and 24 of 25 patients treated intravenously. CONCLUSION: Intranasal PCA with fentanyl was an effective alternative to i.v. PCA in postoperative patients. 相似文献
110.
Els M J J Berns Jan G M Klijn Maxime P Look Nicolai Grebenchtchikov Rolf Vossen Harry Peters Anneke Geurts-Moespot Henk Portengen Iris L van Staveren Marion E Meijer-van Gelder Bert Bakker Fred C G J Sweep John A Foekens 《Clinical cancer research》2003,9(4):1253-1258
PURPOSE: In recent studies, we showed that TP53 gene mutation or high levels of cytosolic vascular endothelial growth factor (VEGF) in estrogen receptor (ER)-alpha-positive primary breast tumors predict a poor disease outcome for patients treated with first-line tamoxifen for advanced disease. Mutant TP53 may up-regulate VEGF, whereas, on the other hand, wild-type TP53 may decrease VEGF production. EXPERIMENTAL DESIGN: In the present study, we aimed to assess the combined predictive value of TP53 gene mutation and VEGF status of 160 advanced breast cancer patients with ER-positive tumors who were treated with tamoxifen (median follow-up from start of tamoxifen treatment, 64 months). To assess TP53 gene mutation status, the entire open reading frame was sequenced; for VEGF status, an ELISA was used. RESULTS: In univariate analysis, both TP53 gene mutation (28% of the tumors) and a VEGF level above the median value were significantly associated with a short progression-free survival, post-relapse overall survival, and a poor rate of response to tamoxifen. In Cox multivariate regression analysis including the traditional predictive factors, the addition of TP53 gene mutation and VEGF status, alone or in combination, significantly predicted a poor efficacy of tamoxifen treatment. When the two factors were combined, a significantly decreased odds ratio was seen for the rate of response (odds ratio, 0.27). Similarly, an increased hazard ratio (HR) was seen for progression-free survival (HR, 2.32) and post-relapse overall survival (HR, 1.68) in the group with mutant TP53 and high VEGF compared with the group with both risk factors absent. CONCLUSIONS: Combined TP53 gene mutation status and high VEGF levels of ER-positive primary breast tumors independently predict a poor course of the disease of patients with advanced breast cancer treated with tamoxifen. These patients, having unfavorable tumor characteristics, might benefit more from other types of (individualized) treatment protocols. 相似文献